Jove
Visualize
Contact Us

Related Experiment Videos

Gabapentin. Pfizer.

Glen Wheeler1

  • 1editor@greyowltutor.com

Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
PubMed
Summary
This summary is machine-generated.

Gabapentin, a GABA analog, effectively treats neuropathic pain by modulating calcium channels and neurotransmitter release. Its unique mechanism involves binding to the alpha-2/delta subunit, impacting central nervous system activity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glutamate as an extracellular signalling molecule in unicellular protists.

Current biology : CB·2026
Same author

A source or sink of carbon dioxide? Understanding the role of extracellular carbonic anhydrase in carbon acquisition by algal cells.

The New phytologist·2026
Same author

Nitrogen status exerts dynamic control over phosphorus sensing and acquisition via PSR1 in colimited marine diatoms.

Science advances·2025
Same author

Abiotic Stress-Induced Chloroplast and Cytosolic Ca<sup>2+</sup> Dynamics in the Green Alga Chlamydomonas reinhardtii.

Plant, cell & environment·2025
Same author

Evolutionary genomics of the emergence of brown algae as key components of coastal ecosystems.

Cell·2024
Same author

Latitudinal gradients and ocean fronts strongly influence protist communities in the southern Pacific Ocean.

FEMS microbiology ecology·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Gabapentin is an approved medication for neuropathic pain in several countries.
  • Regulatory filings for its US indication were underway by late 2001.

Purpose of the Study:

  • To elucidate the pharmacological mechanisms underlying gabapentin's efficacy in neuropathic pain.
  • To understand gabapentin's interaction with neuronal targets and its transport into the central nervous system.

Main Methods:

  • Investigated gabapentin's binding affinity to the alpha-2/delta subunit of voltage-gated calcium channels.
  • Examined gabapentin's interaction with the large neutral amino acid transporter.
  • Explored gabapentin's effects on synaptic transmission and neurotransmitter release.

Main Results:

Related Experiment Videos

  • Gabapentin binds to the alpha-2/delta auxiliary protein of voltage-gated calcium channels.
  • Gabapentin modulates calcium channel activity and neurotransmitter release, potentially explaining its therapeutic effects.
  • Gabapentin is transported into the CNS via the large neutral amino acid transporter.

Conclusions:

  • Gabapentin's mechanism of action involves modulation of voltage-gated calcium channels and neurotransmitter release.
  • The large neutral amino acid transporter is a key pathway for gabapentin's central nervous system entry.
  • These interactions provide a basis for gabapentin's effectiveness in treating neuropathic pain.